# Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

> **NCT03031730** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 35 (actual)

## Conditions studied

- Plasmacytoma
- Recurrent Multiple Myeloma
- Refractory Multiple Myeloma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration and Biopsy
- **DRUG:** Carfilzomib
- **DRUG:** Dexamethasone
- **DRUG:** Dexamethasone Sodium Phosphate
- **PROCEDURE:** Echocardiography
- **DRUG:** Lenalidomide
- **DRUG:** Navtemadlin

## Key facts

- **NCT ID:** NCT03031730
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-14
- **Primary completion:** 2024-07-24
- **Final completion:** 2024-07-24
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** Inadequate accrual rate
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03031730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03031730, "Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03031730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*